TY - JOUR
T1 - Age, disease severity and ethnicity influence humoral responses in a multi-ethnic covid-19 cohort
AU - Smith, Muneerah
AU - Abdesselem, Houari B.
AU - Mullins, Michelle
AU - Tan, Ti Myen
AU - Nel, Andrew J.M.
AU - Al-Nesf, Maryam A.Y.
AU - Bensmail, Ilham
AU - Majbour, Nour K.
AU - Vaikath, Nishant N.
AU - Naik, Adviti
AU - Ouararhni, Khalid
AU - Mohamed-Ali, Vidya
AU - Al-Maadheed, Mohammed
AU - Schell, Darien T.
AU - Baros-Steyl, Seanantha S.
AU - Anuar, Nur D.
AU - Ismail, Nur H.
AU - Morris, Priscilla E.
AU - Mamat, Raja N.R.
AU - Rosli, Nurul S.M.
AU - Anwar, Arif
AU - Ellan, Kavithambigai
AU - Zain, Rozainanee M.
AU - Burgers, Wendy A.
AU - Mayne, Elizabeth S.
AU - El-Agnaf, Omar M.A.
AU - Blackburn, Jonathan M.
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5
Y1 - 2021/5
N2 - The COVID-19 pandemic has affected all individuals across the globe in some way. Despite large numbers of reported seroprevalence studies, there remains a limited understanding of how the magnitude and epitope utilization of the humoral immune response to SARS-CoV-2 viral anti-gens varies within populations following natural infection. Here, we designed a quantitative, multiepitope protein microarray comprising various nucleocapsid protein structural motifs, including two structural domains and three intrinsically disordered regions. Quantitative data from the microarray provided complete differentiation between cases and pre-pandemic controls (100% sensitivity and specificity) in a case-control cohort (n = 100). We then assessed the influence of disease severity, age, and ethnicity on the strength and breadth of the humoral response in a multi-ethnic cohort (n = 138). As expected, patients with severe disease showed significantly higher antibody titers and interestingly also had significantly broader epitope coverage. A significant increase in antibody titer and epitope coverage was observed with increasing age, in both mild and severe disease, which is promising for vaccine efficacy in older individuals. Additionally, we observed significant differences in the breadth and strength of the humoral immune response in relation to ethnicity, which may reflect differences in genetic and lifestyle factors. Furthermore, our data enabled localization of the immuno-dominant epitope to the C-terminal structural domain of the viral nucleocapsid protein in two independent cohorts. Overall, we have designed, validated, and tested an advanced serological assay that enables accurate quantitation of the humoral response post natural infection and that has revealed unexpected differences in the magnitude and epitope utilization within a population.
AB - The COVID-19 pandemic has affected all individuals across the globe in some way. Despite large numbers of reported seroprevalence studies, there remains a limited understanding of how the magnitude and epitope utilization of the humoral immune response to SARS-CoV-2 viral anti-gens varies within populations following natural infection. Here, we designed a quantitative, multiepitope protein microarray comprising various nucleocapsid protein structural motifs, including two structural domains and three intrinsically disordered regions. Quantitative data from the microarray provided complete differentiation between cases and pre-pandemic controls (100% sensitivity and specificity) in a case-control cohort (n = 100). We then assessed the influence of disease severity, age, and ethnicity on the strength and breadth of the humoral response in a multi-ethnic cohort (n = 138). As expected, patients with severe disease showed significantly higher antibody titers and interestingly also had significantly broader epitope coverage. A significant increase in antibody titer and epitope coverage was observed with increasing age, in both mild and severe disease, which is promising for vaccine efficacy in older individuals. Additionally, we observed significant differences in the breadth and strength of the humoral immune response in relation to ethnicity, which may reflect differences in genetic and lifestyle factors. Furthermore, our data enabled localization of the immuno-dominant epitope to the C-terminal structural domain of the viral nucleocapsid protein in two independent cohorts. Overall, we have designed, validated, and tested an advanced serological assay that enables accurate quantitation of the humoral response post natural infection and that has revealed unexpected differences in the magnitude and epitope utilization within a population.
KW - Epitope coverage
KW - Humoral response
KW - Immunoassay
KW - Protein microarray
KW - Quantitative antibody binding
KW - SARS-CoV-2 antibodies
KW - SARS-CoV-2 nucleocapsid protein
UR - http://www.scopus.com/inward/record.url?scp=85105189107&partnerID=8YFLogxK
U2 - 10.3390/v13050786
DO - 10.3390/v13050786
M3 - Article
C2 - 33925055
AN - SCOPUS:85105189107
SN - 1999-4915
VL - 13
JO - Viruses
JF - Viruses
IS - 5
M1 - 786
ER -